Shares rally on buyout buzz: Viking Therapeutics stock surged as much as 15% early Monday before settling up 3%, fueled by social media chatter around potential acquisition interest from major players like Novo Nordisk and AbbVie. Traders highlighted disappointing results from Novo's CagriSema as a catalyst, positioning Viking's VK2735 as a superior contender in the obesity space.
Technical breakout gains traction: Enthusiasm built on chart patterns showing a decisive trendline break, with investors adding positions and eyeing targets well above current levels. Options flow reflected confidence, including sizable call buys signaling bets on near-term upside amid broader market recovery.
Oral drug prospects shine: Discussions emphasized Viking's dual injectable and promising oral formulations, potentially outpacing rivals in efficacy and convenience. Big pharma pressure mounts as social media users speculate on bidding wars, underscoring the stock's pivotal role in the intensifying obesity drug race.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) has made 0 purchases and 5 sales selling 272,398 shares for an estimated $9,057,043.
- CHARLES A JR ROWLAND sold 60,000 shares for an estimated $2,134,278
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 5 sales selling 63,846 shares for an estimated $2,117,897.
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 5 sales selling 63,846 shares for an estimated $2,113,449.
- MATTHEW W FOEHR sold 16,000 shares for an estimated $561,694
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Viking Therapeutics Hedge Fund Activity
We have seen 210 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 228 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 2,030,259 shares (-78.8%) from their portfolio in Q4 2025, for an estimated $71,424,511
- NORGES BANK removed 1,767,777 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,190,394
- D. E. SHAW & CO., INC. added 1,557,136 shares (+965.0%) to their portfolio in Q4 2025, for an estimated $54,780,044
- BLACKROCK, INC. added 1,015,708 shares (+18.2%) to their portfolio in Q4 2025, for an estimated $35,732,607
- BNP PARIBAS FINANCIAL MARKETS added 836,386 shares (+535.1%) to their portfolio in Q4 2025, for an estimated $29,424,059
- FMR LLC added 767,715 shares (+13.3%) to their portfolio in Q4 2025, for an estimated $27,008,213
- BRAIDWELL LP removed 759,455 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $26,717,626
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Viking Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $VKTX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/29/2025
- JP Morgan issued a "Overweight" rating on 10/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/29/2025
To track analyst ratings and price targets for Viking Therapeutics, check out Quiver Quantitative's $VKTX forecast page.
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 5 analysts offer price targets for $VKTX in the last 6 months, with a median target of $102.0.
Here are some recent targets:
- Edward Nash from Canaccord Genuity set a target price of $107.0 on 11/12/2025
- Hardik Parikh from JP Morgan set a target price of $75.0 on 10/24/2025
- Michael Ulz from Morgan Stanley set a target price of $102.0 on 10/23/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 09/29/2025
- Justin Zelin from BTIG set a target price of $125.0 on 09/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
